Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to -$21.1 million.

  • Pliant Therapeutics' Cash from Operations rose 3467.91% to -$21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.2 million, marking a year-over-year decrease of 1900.59%. This contributed to the annual value of -$155.5 million for FY2024, which is 3363.84% down from last year.
  • According to the latest figures from Q3 2025, Pliant Therapeutics' Cash from Operations is -$21.1 million, which was up 3467.91% from -$40.6 million recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' Cash from Operations registered a high of -$13.7 million during Q1 2021, and its lowest value of -$48.9 million during Q1 2025.
  • Moreover, its 5-year median value for Cash from Operations was -$25.1 million (2023), whereas its average is -$29.1 million.
  • In the last 5 years, Pliant Therapeutics' Cash from Operations plummeted by 34965.26% in 2021 and then soared by 3467.91% in 2025.
  • Pliant Therapeutics' Cash from Operations (Quarter) stood at -$19.9 million in 2021, then tumbled by 57.26% to -$31.2 million in 2022, then increased by 19.65% to -$25.1 million in 2023, then crashed by 89.87% to -$47.7 million in 2024, then skyrocketed by 55.77% to -$21.1 million in 2025.
  • Its Cash from Operations was -$21.1 million in Q3 2025, compared to -$40.6 million in Q2 2025 and -$48.9 million in Q1 2025.